Skip to main content
Article thumbnail
Location of Repository

Role of endocannabinoids in regulating drug dependence

By Daniela Parolaro, Daniela Vigano, Natalia Realini and Tiziana Rubino


This review will discuss the latest knowledge of how the endocannabinoid system might be involved in treating addiction to the most common illicit drugs. Experimental models are providing increasing evidence for the pharmacological management of endocannabinoid signaling not only to block the direct reinforcing effects of cannabis, opioids, nicotine and ethanol, but also for preventing relapse to the various drugs of abuse, including opioids, cocaine, nicotine, alcohol and metamphetamine. Preclinical and clinical studies suggest that the endocannabinoid system can be manipulated by the CB1 receptor antagonist SR141716A, that might constitute a new generation of compounds for treating addiction across different classes of abused drugs

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2004). 21:5344–50.Neuropsychiatric Disease and Treatment 2007:3(6) 721 The endocannabinoid system in drug addiction
    2. (2005). 3,4-Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. Pharmacol Res,
    3. (2001). A cannabinoid mechanism in relapse to cocaine seeking.
    4. (1997). Activation of arachidonic acid-specifi c phospholipase A2 in human neuroblastoma cells after chronic alcohol exposure: prevention by GM1 ganglioside. Alcohol Clin Exp Res,
    5. (2001). Addiction and the brain: the neurobiology of compulsion and its persistence.
    6. (2006). An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives.
    7. (1995). Anandamide decreases naloxoneprecipitated withdrawal signs in mice chronically treated with morphine.
    8. (1976). Attentuation of precipitated abstinence in methadone-dependent rats by delta9-THC.
    9. (1998). Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice. Drug Alcohol Depend,
    10. (1999). Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol,
    11. (2002). Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.
    12. (2002). Blockade by the cannabinoid CB(1) receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats.
    13. (2004). Cannabinoid agonist-induced sensitisation to morphine place preference in mice.
    14. (2005). Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing effi cacy of heroin in rats.
    15. (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.
    16. (2005). Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats.
    17. (2006). Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens.
    18. (2001). Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse.
    19. (2005). Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats.
    20. (2005). Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci,
    21. (2003). Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats.
    22. (2006). Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway.
    23. (2003). Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroinassociated cues in rats.
    24. (2005). Cannabinoid tolerance and dependence: a review of studies in laboratory animals.
    25. (2003). Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice.
    26. (2000). Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice.
    27. (1999). CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats.
    28. (1998). CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats.
    29. (2004). CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.
    30. (2005). CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors.
    31. (1999). Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoyl-phosphatidyl-ethanolamine in SK-N-SH cells.
    32. (2003). Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons.
    33. (2002). Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend,
    34. (2000). Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice.
    35. (2001). Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system.
    36. (2002). Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Res,
    37. (2004). Decreased alcohol selfadministration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice.
    38. (2004). Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice.
    39. (2004). Differences in basal cannabinoid CB1 receptor function in selective brain areas and vulnerability to voluntary alcohol consumption in Fawn Hooded and Wistar rats. Alcohol Alcohol,
    40. (1999). Down-regulation of cannabinoid receptor agonist-stimulated [35S]GTP gamma S binding in synaptic plasma membrane from chronic ethanol exposed mouse. Brain Res,
    41. (1999). Drug addiction as dopamine-dependent associative learning disorder.
    42. (2001). Drug addiction, dysregulation of reward, and allostasis.
    43. (2003). Drug addiction.
    44. (1992). Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci,
    45. (1998). Effect of chronic ethanol exposure on mouse brain arachidonic acid specifi c phospholipase A2. Biochem Pharmacol,
    46. (2001). Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcohol Clin Exp Res,
    47. (2004). Effects of Rimonabant in the reduction of major cardiovascular risk factors Results from the STRATUS-US trial (smoking cessation in smokers motivated to quit). In american college of cardiology 53rd annual scientifi c session;
    48. (2001). Effects of SR141716A on ethanol and sucrose self-administration. Alcohol Clin Exp Res,
    49. (2005). Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.
    50. (2005). Endocannabinoid signaling system and brain reward: emphasis on dopamine.
    51. (2003). Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its agedependent decline in mice.
    52. (2005). Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol Biochem Behav,
    53. (2004). Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade.
    54. (2005). Endocannabinoids and drug dependence.
    55. (2005). Endocannabinoids in the central nervous system: from neuronal networks to behavior. Curr Drug Targets CNS Neurol Disord,
    56. (2001). Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
    57. (2005). Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization.
    58. (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration.
    59. (1996). Genetic differences in tolerance and sensitization to the sedative/hypnotic effects of alcohol.
    60. (2006). Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference [online].
    61. (2005). Identifi cation and functional characterization of brainstem cannabinoid CB2 receptors.
    62. (2006). Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice.
    63. (1999). Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist.
    64. (2004). Intravenous heroin self-administration decreases GABA effl ux in the ventral pallidum: an in vivo microdialysis study in rats.
    65. (2006). Involvement of the endocannabinoid system in drug addiction. Trends Neurosci,
    66. (2005). Lack of CB1 cannabinoid receptor impairs cocaine self-administration.
    67. (2002). Lack of CB1 cannabinoid receptors modifi es nicotine behavioural responses, but not nicotine abstinence.
    68. (2004). Learning mechanisms in addiction: synaptic plasticity in the ventral tegmental area as a result of exposure to drugs of abuse. Annu Rev Physiol,
    69. (2000). Long-term treatment with SR141716A, the CB1 receptor antagonist, infl uences morphine withdrawal syndrome. Life Sci,
    70. (1994). Low level of response to alcohol as a predictor of future alcoholism.
    71. (2004). Marijuana and cannabinoid regulation of brain reward circuits.
    72. (2005). Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav,
    73. (2004). Molecular mechanisms of drug addiction.
    74. (2002). Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors.
    75. (1977). Naloxone-induced or postwithdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats.
    76. (2004). Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev,
    77. (2003). Neuromorphological background of cannabis addiction.
    78. (2003). New advances in the identifi cation and physiological role of the different components of the endogenous cannabinoidi system.
    79. (2005). Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist,
    80. (2001). Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
    81. (2001). Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction.
    82. (1998). Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR141716. Alcohol Alcohol,
    83. (2003). Region-dependent changes in endocannabinoid transmission in the brain of morphinedependent rats.
    84. (2004). Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.
    85. (2002). Role of the endocannabinoid system in MDMA intracerebral self-administration in rats.
    86. (1997). Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors.
    87. (2002). SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopaminereleasing effects of nicotine in rats. Behav Pharmacol,
    88. (2003). SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats.
    89. (2002). Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats.
    90. (2002). Study of cannabinoid dependence in animals. Pharmacol Ther,
    91. (2004). Suppressing effect of the cannabinoid CB1 receptor antagonist, SR141716, on alcohol’s motivational properties in alcohol-preferring rats.
    92. (2005). Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol,
    93. (2001). The cannabinoid receptor antagonist SR141716 prevents acquisition of drinking behavior in alcohol-preferring rats.
    94. (2005). The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav,
    95. (2006). The mesolimbic dopamine system: the fi nal common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev,
    96. (1999). The motivation for beer in rats: effects of ritanserin, naloxone and SR141716.
    97. (2004). The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.
    98. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.